Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 1/2012

01-02-2012 | Letter to the Editor

RE: Mass lesions in chronic pancreatitis: benign or malignant? An “evidence-based practice” approach. A caveat regarding autoimmune pancreatitis

Authors: J. F. Gerstenmaier, D. E. Malone

Published in: Abdominal Radiology | Issue 1/2012

Login to get access

Excerpt

In a recent ‘Online First’ article in Abdominal Imaging (3 November 2010) [1], we presented current best evidence about the imaging differentiation between benign and malignant mass lesions in the setting of chronic pancreatitis. A diagnostic algorithm was proposed. …
Literature
1.
Gerstenmaier JF, Malone DE (2010) Mass lesions in chronic pancreatitis: benign or malignant? An “evidence-based practice” approach. Abdom Imaging. doi:10.​1007/​s00261-010-9658-9
2.
3.
4.
Ichikawa T, Sou H, Araki T, et al. (2001) Duct-penetrating sign at MRCP: usefulness for differentiating inflammatory pancreatic mass from pancreatic carcinomas. Radiology 221(1):107–116PubMedCrossRef
5.
6.
7.
Moon SH, Kim MH, Park DH, et al. (2008) Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut 57(12):1704–1712. doi:10.​1136/​gut.​2008.​150979 PubMedCrossRef
8.
Lee TY, Kim MH, Park do H, et al. (2009) Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 193(2):343–348. doi:10.​2214/​AJR.​08.​2297 PubMedCrossRef
9.
Kamisawa T, Takum K, Anjiki H, et al. (2010) FDG-PET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 57(99–100):447–450PubMed
10.
11.
Deshpande V, Mino-Kenudson M, Brugge WR, et al. (2005) Endoscopic ultrasound guided fine needle aspiration biopsy of autoimmune pancreatitis: diagnostic criteria and pitfalls. Am J Surg Pathol 29(11):1464–1471. doi:00000478-200511000-00007[pii] PubMedCrossRef
12.
13.
Metadata
Title
RE: Mass lesions in chronic pancreatitis: benign or malignant? An “evidence-based practice” approach. A caveat regarding autoimmune pancreatitis
Authors
J. F. Gerstenmaier
D. E. Malone
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 1/2012
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-011-9746-5

Other articles of this Issue 1/2012

Abdominal Radiology 1/2012 Go to the issue

ReviewPaper

Whole-body MR/PET: applications in abdominal imaging

OriginalPaper

Small intestinal vascular malformation bleeding: diagnosis by double-balloon enteroscopy combined with abdominal contrast-enhanced CT examination

OriginalPaper

Diagnostic yield of capsule endoscopy for gastric diseases

OriginalPaper

Intraductal papillary mucinous neoplasms of the pancreas complicated with intraductal hemorrhage, perforation, and fistula formation: CT and MR imaging findings with pathologic correlation

OriginalPaper

Obscure and occult gastrointestinal bleeding: comparison of different imaging modalities

Pictorial Essay

Relapse of Crohn’s disease following ileal pouch-anal anastomosis: MDCT and MR features
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits